Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Klaria Pharma Holding AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.19.
During the past 3 years, the average EBIT per Share Growth Rate was 42.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Klaria Pharma Holding AB's EBIT per Share or its related term are showing as below:
OSTO:KLAR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.9 Med: -13.25 Max: 44
Current: 42.5
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Klaria Pharma Holding AB was 44.00% per year. The lowest was -45.90% per year. And the median was -13.25% per year.
OSTO:KLAR's 3-Year EBIT Growth Rate is ranked better than 85.71% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs OSTO:KLAR: 42.50
Klaria Pharma Holding AB (OSTO:KLAR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Klaria Pharma Holding AB EBIT per Share Related Terms
Klaria Pharma Holding AB EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klaria Pharma Holding AB (OSTO:KLAR) has a EBIT per Share of kr-0.19 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Klaria Pharma Holding AB and its competitors. According to the industry distribution chart, Klaria Pharma Holding AB ranks #116 out of 812 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is Klaria Pharma Holding AB's EBIT per Share too high?
Klaria Pharma Holding AB's current EBIT per Share is kr-0.19. Based on the distribution chart, Klaria Pharma Holding AB ranks #116 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Klaria Pharma Holding AB has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Klaria Pharma Holding AB ranks #116 out of 812 companies for EBIT per Share. This places Klaria Pharma Holding AB in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Klaria Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current EBIT per Share is kr-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (OSTO:KLAR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.32, compared to a current price of kr0.79 — trading 146.3% above its estimated fair value. The current EBIT per Share is kr-0.19. Klaria Pharma Holding AB's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Klaria Pharma Holding AB (OSTO:KLAR), the current EBIT per Share is kr-0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (OSTO:KLAR) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of kr0.79 is trading 146.3% above its estimated GF Value™ of kr0.32.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:KLAR:
EBIT per Share: kr-0.19
GF Value™: kr0.32 vs. price of kr0.79 (146.3% above fair value)
No single metric tells the full story. See the OSTO:KLAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
9GF Score
Get the complete analysis for OSTO:KLAR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:KLAR has been successfully added to your 
